Development
Emergent BioSolutions Inc.
EBS
$6.22
-$0.02-0.32%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -16.23% | 12.76% | 40.52% | -46.31% | -54.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -16.23% | 12.76% | 40.52% | -46.31% | -54.34% |
| Cost of Revenue | 2.55% | -4.61% | -3.40% | -4.76% | -26.96% |
| Gross Profit | -51.71% | 76.91% | 551.05% | -125.64% | -73.27% |
| SG&A Expenses | -3.96% | 5.13% | 15.97% | 18.51% | -0.85% |
| Depreciation & Amortization | -9.50% | 16.43% | 15.00% | 21.43% | 27.86% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.03% | -0.77% | 2.32% | 3.03% | -18.97% |
| Operating Income | -1,790.00% | 73.38% | 120.67% | -2,195.65% | -99.06% |
| Income Before Tax | 11.24% | -295.68% | -188.34% | -4,139.47% | -122.95% |
| Income Tax Expenses | -189.29% | -112.56% | 145.43% | 22,000.00% | -92.84% |
| Earnings from Continuing Operations | 26.12% | -202.41% | -391.82% | -4,845.95% | -135.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.12% | -202.41% | -391.82% | -4,845.95% | -135.39% |
| EBIT | -1,790.00% | 73.38% | 120.67% | -2,195.65% | -99.06% |
| EBITDA | -189.43% | 1,350.00% | 207.48% | -405.22% | -92.91% |
| EPS Basic | 28.96% | -191.31% | -385.03% | -4,893.70% | -137.95% |
| Normalized Basic EPS | -1,805.67% | 49.38% | 80.58% | -4,721.13% | -101.07% |
| EPS Diluted | 28.96% | -190.57% | -385.21% | -4,900.00% | -138.39% |
| Normalized Diluted EPS | -1,805.67% | 49.38% | 80.58% | -4,721.13% | -101.09% |
| Average Basic Shares Outstanding | 4.01% | 3.81% | 1.40% | -0.99% | -6.73% |
| Average Diluted Shares Outstanding | 4.01% | 3.81% | 1.40% | -0.99% | -7.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |